|
|
Pacgen Acquires XPhase, Which Owns Rights to China Anti-Anxiety Drug
publication date: Apr 28, 2009
Pacgen Biopharmaceuticals (TSXV: PGA) of Vancouver, Canada signed a letter of intent to negotiate the purchase of XPhase Pharmaceuticals of Toronto. The leadership of XPhase will take over management of Pacgen. As its major asset, XPhase has a signed letter of intent for global rights (ex-China) to a new anti-anxiety chemical entity, named AF-5, discovered by the Institute of Materia Medica, Chinese Academy of Medical Science in Beijing (IMM). In China, IMM has obtained SFDA approval to begin clinical trials of AF-5 and is expected to initiate a Phase I test of the entity in early 2009. More details...
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|